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ABSTRACT
To investigate the discrepancy between 11C-methionine (MET) positron emission tomography (PET) and MRI results in primary 
glioblastoma multiforme (GBM) through three-dimensional (3D) volumetric analysis, we retrospectively analysed patients with 
primary GBM who underwent preoperative 3D MRI and MET PET and were operated between June 2016 and January 2017. 
Tumour delineation and volumetric analysis were conducted using MRIcron software. Tumour volumes defined by MRI (VMRI) 
were manually drawn slice by slice in axial and sagittal or coronal images of enhanced T1 sequence, while metabolic tumour 
volumes were automatically segmented in MET PET (VMET) based on three (frontal, occipital and temporal) 3D reference volu-
mes of interest (VOI). Discrepancies were evaluated in terms of both absolute volume and percentage on the combined images. 
MET PET contours contained and extended beyond MRI contours in all five patients; in a subset of cases, MET PET contours ex-
tended to the contralateral hemisphere. The discrepancy between MET uptake and MRI results was 27.67 cm3 (4.20–51.20 cm3), 
i.e. approximately 39.0% (17.4–64.3%) of the metabolic tumour volume was located outside the volumes of the Gd-enhanced 
area. Metabolic tumour volume is substantially underestimated by Gd-enhanced area in patients with primary GBM. Quantita-
tive volumetric information derived from MET uptake is useful in defining tumour targets and designing individualised therapy 
strategies in primary GBM.
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Introduction
Glioma is the most common primary brain tumour 
of the central nervous system in adults (38%). The World 
Health Organisation (WHO) has established criteria for 
classifying glioma into four histological grades according 
to the tumour’s pathological morphology [1]. Glioblastoma 
multiforme (GBM), the highest grade glioma, is intensively in-
filtrative and has a diffuse border with the brain parenchyma. 
As a consequence, defining tumour boundaries for treatment 
is challenging. Magnetic resonance imaging (MRI) is the most 
widely used imaging modality and the standard reference for 
diagnosis, therapy planning and follow-up of GBM tumours. 
Inhomogeneous enhancement and necrosis characterise the 
majority of GBM lesions [2]. The standard MRI sequence 
for calculating tumour volume and planning the extent of 
surgery for high-grade gliomas is gadolinium (Gd) enhanced 
T1-weighted imaging [3]. However, MRI cannot precisely 
delineate tumour volume and is insufficient in helping to 
achieve total resection of glioblastoma, because T2-weighted 
imaging can incorporate both tumour tissue and perifocal 
oedema [4], and high-grade glioma cells are not limited to the 
Gd-enhanced volume in MRI T1 images [5, 6] and in fact can 
be located up to 30 mm beyond the Gd-enhanced area [7]. 
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Positron emission tomography (PET) with metabolic 
tracers has played an important role in neurooncology [8, 9]. 
Radiolabelled amino acids, such as 11C-methionine (MET) 
PET, reflect the extent of tumour boundaries in GBM more 
reliably than CT or MRI, because Gd-enhanced areas in 
MRI represent disruptions of the brain-blood barrier, while 
MET uptake correlates with tumour cell density or prolife-
rative capability, thus more closely reflecting the properties 
of glioblastoma multiforme [10-13]. Complete resection of 
MET uptake areas has been shown to increase survival of 
high-grade glioma patients in previous studies [14, 15]. Both 
qualitative and semiquantitative analysis of Gd-enhanced 
T1 and MET PET in GBM have revealed discrepancies 
between the two modalities [7, 16, 17], but these studies 
reported neither volumetric analysis of entire tumours nor 
volume information of any sort. To date, only a few studies 
have conducted volumetric calculation [18, 19], and no 3D 
volumetric analysis of discrepancies between MRI and MET 
PET has been performed focusing on primary GBM.
The current study therefore aimed to investigate differen-
ces in estimates of primary GBM tumour volume based on 
3D MRI and MET PET.
Materials and methods 
Patients
Firstly, we retrospectively reviewed the neurosurgery 
database and found a total of 461 brain tumour operations 
performed between June 2016 and January 2017. Secondly, 
patients were screened for pathological confirmation of 
GBM, with 31 patients thereby selected. Finally, patients 
were required to meet all of the following inclusion criteria: 
(1) they had no prior biopsy or treatment; (2) they had 
available data from preoperative 3D whole brain contrast-
-enhanced MRI and MET PET; and (3) the interval between 
these two examinations was less than seven days. The final 
study population consisted of five patients, whose clinical data 
is set out in Table 1. The protocol of this study was approved 
by the Research Ethics Committee of the Hospital.
Image acquisition
MR images were obtained using a 3.0-Tesla MR scanner 
(Discovery MR750, General Electric, Milwaukee, WI, USA). 
Sagittal 3D T1-weighted images were acquired using a whole 
brain sequence with the following parameters: repetition 
time (TR) = 8.2 ms; echo time (TE) = 3.2 ms; inversion time 
(TI) = 450 ms; flip angle (FA) = 12°; field of view (FOV) 
= 256 mm × 256 mm; and matrix = 256 × 256; slice thickness 
= 1 mm, no gap.
PET images were acquired with a dedicated PET/CT 
scanner (Discovery LS, GE Medical Systems, Milwaukee, 
WI, USA). Patients fasted for at least six hours before exa-
mination; a dose of 555–740 MBq (15–20 mCi) MET was 
injected intravenously within one minute. Static emission 
scanning was performed for a minimum of 20 minutes after 
MET injection in 3D mode (FOV = 150 mm×150 mm, slice 
thickness = 5.0 mm, slice gap 4.5 mm, matrix = 128 × 128). For 
attenuation correction, we acquired a non-contrast-enhanced, 
low-dose CT scan (slice thickness = 2.5 mm, slice gap = 0, 
matrix = 512 × 512). MET uptake in the tumour and in normal 
cortex was expressed as standard uptake value (SUV). The 
ratio of tumour SUV to normal SUV in contralateral gray 
matter (TNR) was calculated for each tumour by a nuclear 
medicine physician trained in brain PET. For surgical plan-
ning, the TNR was adjusted to 1.3 to define the tumour target.
Image processing and volumetric analysis
The MET PET and MRI images were first transferred 
from DICOM to NIfTI format for viewing and processing 
using MRIcron software (http://www.mricro.com; University 
of South Carolina, Columbia, SC, USA). Images were then 
coregistered using Statistical Parametric Mapping 12 software 
(http://www.fil.ion.ucl.ac.uk/spm/; Wellcome Department of 
Cognitive Neurology, London, UK).
Tumour delineation and volumetric analysis of MRI and 
MET PET images were performed in MRIcron. The tumour 
was defined as previously described [18, 20]. Tumour volu-
mes defined by MRI (VMRI) were manually drawn slice by 
slice in axial and sagittal or coronal images of the enhanced 
T1 sequence by two skilled radiologists. The metabolic tumour 
volume defined by MET uptake (VMET) was automatically 
segmented based on image thresholding. Firstly, three sphe-
rical regions of 10-mm radius were drawn in the unaffected 
contralateral frontal, occipital and temporal parenchyma as 
reference VOI in order to calculate normal SUV. Secondly, 
VMET was automatically segmented by image thresholding 
(TNR = 1.3) as defined above. For tumour volume compari-
sons between MET PET and the corresponding MRI, contours 
were extended to central areas without MET uptake related 
to necrosis. High uptake areas beyond the tumour were ma-
nually excluded in order to avoid inclusion of physiological 
MET uptake in normal tissues. Thirdly, in order to express 
tumour volume differences between the two modalities, vo-
lume of discrepancy-MET (dis-MET: VMET not included in 
VMRI) was evaluated (both in terms of absolute volume and 
percentage) using the ‘Overlay Comparisons’ and ‘Descriptive’ 
functions included in MRIcron.
Statistical analysis
Statistical analyses were performed using SPSS 19.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Descriptive statistics were 
expressed as median and range [median (range)]. Values of 
p < 0.05 (two-tailed) were considered statistically significant.
Results
Patient characteristics and volumetric data for the whole 
group are summarised in Table 1.
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On MET PET, uptake in the metabolically active tumour 
was clearly differentiated from that of normal brain tissue for 
all five patients. Visual analysis of coincidence and discre-
pancy between MET high uptake volumes and Gd-enhanced 
MRI demonstrated that MET PET contours contained and 
extended beyond most MRI contours. Furthermore, MET 
PET volumes even extended along commissural fibres to the 
contralateral cerebral hemisphere (Figure 1). Moreover, the 
overall shape of MET high uptake volumes was asymmetrical 
and irregular.
In volumetric analysis, the discrepancy of MET uptake was 
27.67 cm³ (4.20–51.20 cm³), i.e. about 39.0% (17.4–64.3%) 
of metabolically defined tumour volumes were located beyond 
the Gd-enhanced regions (Figure 2).
Discussion
Glioblastoma multiforme is known for its invasive and 
aggressive behaviour, and there is no distinct margin with the 
brain parenchyma [1]. Gd-enhanced T1-weighted MRI is the 
standard MRI sequence for tumour delineation and defining 
resection targets for high-grade gliomas [3]. Timothy et al. 
conducted the largest systematic review and the only quan-
titative meta-analysis to investigate associations between the 
extent of resection and overall progression-free survival in 
GBM. They concluded that compared to subtotal resection, 
gross total resection substantially improved overall and pro-
gression-free survival [21]. Although cytoreductive surgery 
is the cornerstone of therapy in GBM, no consensus exists 
regarding the optimal extent of tumour resection necessary 
to improve survival [11]. Most GBM still recurs even after 
removal of all contrast-enhanced volumes on T1-weighted 
MRI. Therefore techniques such as metabolic imaging are 
needed to improve resection rates and the safety of surgery.
A subset of studies has reported that MET uptake reﬂects 
proliferation potential and angiogenic capability in gliomas 
[22, 23]. In these studies, MET uptake was compared to 
the Ki-67 labelling index and microvessel density non-
-stereotactically. To overcome this problem, Yoshiko et al. 
conducted a stereotactic comparison of MET PET images 
and the resulting histology; they confirmed that MET uptake 
correlates with tumour cell density rather than with mic-
rovessel density in glioma [10]. They concluded that MET 
uptake correlates with tumour cell density (proliferative 
capability). Moreover, Yoo et al. [15] reported that metabolic 
tumour volume on MET PET is a significant and independent 
prognostic factor for progression-free survival in high-grade 
glioma; they recommended volumetric analysis of MET for 
better prognostication. Singhal et al. [24] compared MET to 
18F-fluorodeoxyglucose (FDG) and contrast enhancement 
on MRI, suggesting that MET PET can predict prognosis in 
gliomas more accurately than FDG PET and MRI. In sum-
mary, MET is more accurate in delineating the tumour and 
defining the extent of resection targets.
Given the different physiological bases of Gd-enhanced 
MRI and MET uptake, discrepancies between MRI and 
Table 1.  Patient characteristics and volumetric analysis of MRI and MET PET
No. Sex Age Location 
(side)
VMRI 
(cm³)
VMET 
(cm³)
dis-MET 
(cm³)
dis-MET 
(%)
1 F 63 Frontal(R) 53.81 93.31 45.15 48.4
2 M 66 Temporal(L) 43.86 59.20 16.80 28.4
3 M 71 Occipital(L) 38.48 57.43 20.98 36.5
4 F 66 Frontal(R) 22.24 24.12 4.20 17.4
5 F 65 Frontal(L) 28.92 79.63 51.20 64.3
F femal, GBM glioblastoma multiforme, L left, M male, No. patient number, R right
Figure 1. Visual comparison of enhanced MRI with MET PET of primary GBM. A: Tumour contours (green line) in Gd-enhanced T1 MRI. 
B: Tumour contours comparison in the overlap of MET (TNR = 1.3) and corresponding MRI demonstrated that MET-defined tumour volume 
extended along commissural fibres of fornix to the contralateral hemisphere. C: General MET PET image of GBM
A B C
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Figure 2. Volumetric analysis of enhanced MRI and MET PET in primary GBM (case 1). Letters A, B and C represent axial, coronal and sa-
gittal views of the same origin, respectively. Row 1: tumour contour (green line) delineated manually in each slice of Gd-enhanced T1 MRI 
images. Row 2: tumour volume calculated by MRIcron (VMRI is 53.81 cm³). Row 3: MET PET images minimally processed to show MET high 
uptake of GBM. Row 4: Automatically defined metabolic tumour volume (VMET) calculated as 93.31 cm3 (setting threshold: TNR = 1.3). 
Row 5: tumour volume comparisons between MET PET and the corresponding MRI, dis-MET (volumes contained in MET but not in MRI) is 
48.4%
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corresponding MET PET images are to be expected. PET 
metabolic imaging using radiolabelled amino acids, such as 
MET, has been successfully combined with MRI to produce 
a powerful and reliable technique for defining GBM target 
volumes in neuronavigation surgery and radiotherapy [17].
To examine the distribution of metabolic abnormalities 
associated with glioblastoma multiforme relative to MRI, 
Miwa et al. superimposed contemporaneous MRI on corre-
sponding MET-PET images in 10 patients with newly diagno-
sed GBM prior to treatment. They found that the MET volume 
included and exceeded the entire Gd-enhanced volume and 
that 99.8% of the MET-enhanced area was located within 
30 mm surrounding of the Gd-enhanced area [7], although 
the MET volume was assessed by qualitative visual analysis. 
Galldiks et al. investigated the relationship between MET 
and Gd-enhanced MRI through volumetric calculation. They 
reported that the metabolically active tumour volume may be 
substantially underestimated by Gd-enhanced volume, and 
they also showed a positive correlation between MET uptake 
and the volumes of Gd-enhanced area [19]. However, the re-
ference ROI in that study was a two-dimensional circular area 
that contained limited volumetric information. Moreover, 
all 12 patients were recurrent GBM. Qualitative, semiquan-
titative and quantitative methods have all been applied to 
analyse discrepancies and coincidences between MET PET 
and MRI; these methods have illustrated the importance of 
including those areas in the treatment plan [7, 19]. To date, 
there has been no precise 3D volumetric study focused on 
primary GBM.
The aim of the present study was to investigate discrepan-
cies of tumour volumes in primary GBM based on precise vo-
lumetric analysis of two imaging modalities. In particular, we 
investigated tumour volumes metabolically estimated using 
MET PET that extended regions of Gd-enhanced area. To 
improve precision and recall, we set strict inclusion criteria. 
Due to the high proliferation rate of tumour cells, we limited 
the interval between the MRI and the PET examinations to 
seven days; this minimised discrepancies between the two 
image modalities due to tumour growth. This interval was 
significantly shorter than those used in previous studies 
[18, 19]. Furthermore, to obtain representative reference VOI 
and to segment VMET, we selected three spherical regions with 
a 10 mm radius in the unaffected contralateral frontal, occipi-
tal and temporal parenchyma. Compared to image processing 
software in previous studies [19], MRIcron is convenient 
to acquire and simple to operate. These properties make it 
suitable and popular for practical clinical use.
As described above, we found that MET PET contours 
contained and extended beyond most MRI contours in all 
five patients; this finding was in accordance with the study 
of Miwa et al. [7]. However, in our study, volumes of high 
MET uptake were not limited to within 30 mm of the Gd-
-enhanced area. Rather, they extended along commissural 
fibres to the contralateral cerebral hemisphere. This also 
explains why GBM may exhibit higher proliferation rates 
in some regions, resulting in asymmetrical and irregular 
MET PET images.
In volumetric analyses, approximately 39.0% (17.4– 
–64.3%) of metabolic tumour volume was located beyond 
the Gd-enhanced area. Javier et al. previously performed 
volumetric research to analyse the contributions of MRI and 
MET PET to tumour target volume estimates in both high- 
and low-grade glioma. According to this study, approximately 
30.22% (17.4–64.3%) of MET-defined tumour volume did not 
overlap with MRI-defined volumes in GBM [18]. However, 
it must be noted that seven out of ten (70%) patients were 
recurrent GBM. This clinical profile significantly affected the 
analysis, as the authors included the resection cavity when 
defining tumour volume. These MET-specific volumes are 
especially important. Recently, John et al. reported findings 
that support the interpretation that MET delineates non-con-
trast enhancing tumour regions at high risk for recurrence 
[12]. Although we performed no statistical estimation, due 
to our limited sample size, our results nevertheless indicated 
larger VMET estimates associated with VMRI, in line with 
a previous study [19].
Concerning the specific results in the volumetric analysis 
observed in our group, it is relevant to discuss the inclusion of 
volumes with a lack of MET uptake related to central necrosis 
in the final volume of MET PET. These areas were included 
in order to facilitate comparison with MRI, which typically 
includes these areas defining the final surgical target volume.
Limitations
Our study was performed in a clinical setting, and there-
fore may reflect a natural bias. Additionally, exact volumetric 
calculation and comparison could only be performed on pa-
tients with presurgical 3D acquisition of both Gd-enhanced 
MRI and MET PET. As a consequence, the number of patients 
limits further statistical calculation, and may constrain our 
conclusions. Although we selected skilled radiologists to 
delineate MRI volume, there will have been subjective error 
due to the manually drawn contours.
Conclusion
GBM is a diffusely infiltrating and widespread malig-
nant neoplasm that, even at the time of diagnosis, typically 
invades multiple lobes and both hemispheres of the brain. 
Metabolic tumour volume is substantially underestimated by 
Gd-enhanced area in primary GBM. MET PET contours 
contain and extend beyond most MRI contours. In our 
experience, approximately 40% of MET high uptake volumes 
are not included in MRI tumour volumes. Quantitative vo-
lumetric information derived from MET uptake is helpful in 
defining tumour targets and designing individualised therapy 
strategies for primary GBM.
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